ProQR Therapeutics (NASDAQ:PRQR) Now Covered by Analysts at Cantor Fitzgerald

Cantor Fitzgerald began coverage on shares of ProQR Therapeutics (NASDAQ:PRQR - Free Report) in a research note issued to investors on Tuesday, Marketbeat reports. The firm issued an overweight rating and a $8.00 target price on the biopharmaceutical company's stock. Cantor Fitzgerald also issued estimates for ProQR Therapeutics' FY2025 earnings at ($0.39) EPS.

A number of other equities analysts have also weighed in on the stock. Evercore ISI initiated coverage on shares of ProQR Therapeutics in a report on Tuesday, April 29th. They issued an "outperform" rating and a $5.00 price target on the stock. HC Wainwright boosted their price target on ProQR Therapeutics from $10.00 to $12.00 and gave the company a "buy" rating in a research report on Friday, March 14th. Oppenheimer initiated coverage on ProQR Therapeutics in a report on Friday, January 10th. They issued an "outperform" rating and a $15.00 price objective on the stock. Citigroup upgraded ProQR Therapeutics from a "neutral" rating to a "buy" rating and set a $4.00 target price for the company in a report on Monday, March 10th. Finally, Chardan Capital restated a "buy" rating and issued a $4.00 price target on shares of ProQR Therapeutics in a report on Friday, March 14th. One analyst has rated the stock with a sell rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $8.75.

ProQR Therapeutics Trading Up 15.7 %

Shares of NASDAQ PRQR traded up $0.27 on Tuesday, reaching $1.99. 1,450,411 shares of the company traded hands, compared to its average volume of 611,137. The company has a 50 day moving average of $1.56 and a 200 day moving average of $2.48. ProQR Therapeutics has a fifty-two week low of $1.07 and a fifty-two week high of $4.62. The stock has a market capitalization of $209.37 million, a PE ratio of -6.22 and a beta of 0.35.

Institutional Trading of ProQR Therapeutics

Several large investors have recently modified their holdings of PRQR. Jane Street Group LLC acquired a new position in shares of ProQR Therapeutics in the fourth quarter worth about $30,000. Invesco Ltd. purchased a new stake in ProQR Therapeutics during the 4th quarter worth approximately $32,000. Alpine Global Management LLC acquired a new position in shares of ProQR Therapeutics in the 4th quarter valued at approximately $39,000. Two Sigma Securities LLC purchased a new position in shares of ProQR Therapeutics during the 4th quarter valued at approximately $40,000. Finally, Vontobel Holding Ltd. acquired a new stake in shares of ProQR Therapeutics during the first quarter worth approximately $48,000. 32.65% of the stock is currently owned by institutional investors and hedge funds.

About ProQR Therapeutics

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).